Real-world weight changes in people with HIV-1 at risk of weight gain (female, Black or Hispanic) switching from integrase strand transfer inhibitors

J Comp Eff Res. 2023 Jan;12(1):e220147. doi: 10.2217/cer-2022-0147. Epub 2022 Nov 29.

Abstract

Aim: Compare weight changes between people living with HIV-1 (PLWH) at high risk of weight gain (females, Blacks or Hispanics) switching from an integrase strand transfer inhibitor (INSTI) to a protease inhibitor (PI) or another INSTI. Materials & methods: Mean weight changes from pre-switch to up-to-12 months post-switch were retrospectively compared between PLWH switching to a PI or INSTI. Results: 356 PLWH were eligible. At 9- and 12-month post-switch, weight increases were observed for INSTI (weight: +1.55 kg and +1.59 kg), while decreases were observed for PI (-0.23 kg and -1.59 kg); differences between cohorts widened over time. Conclusion: These data suggest that switching off an INSTI may be a management tool to mitigate or reverse weight gain.

Keywords: BMI; HIV; integrase stand transfer inhibitor; observational study; protease inhibitor; weight gain.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Black or African American
  • Female
  • HIV Infections* / drug therapy
  • HIV Integrase Inhibitors* / pharmacology
  • HIV Integrase Inhibitors* / therapeutic use
  • HIV-1*
  • Hispanic or Latino
  • Humans
  • Integrases / therapeutic use
  • Retrospective Studies
  • Weight Gain

Substances

  • HIV Integrase Inhibitors
  • Integrases